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Purpose of the study
To investigate the outcome of treatment for chronic hepa-
titis C virus (HCV) infection in HIV-infected patients in
our center.
Methods
We reviewed the files of all HIV-infected patients who ini-
tiated a therapy for HCV infection from 2000 to June
2008. Patients of all genotypes were assigned to 48 weeks
of pegylated interferon alpha-2b (1.5 μg/kg/week) or
alpha-2a (180 μg/week) combined with ribavirin (800–
1200 mg daily, according to patient's weight). HCV ther-
apy was discontinued after 6 months in case of persistent
HCV viremia (and from June 2007 onwards after 3
months if HCV-RNA load failed a 2-log decrease).
Summary of results
HCV genotyping was documented in 96 co-infected
patients, including 47 with genotype 1 (49%), two with
genotype 2 (2%), 17 with genotype 3 (18%), and 30 with
genotype 4 (31%). Liver biopsy was performed in 64
patients and revealed moderate fibrosis (METAVIR F2) in
16 patients (25%) and advanced stages (F3-F4) in 27
(42%). Treatment was initiated in 46 (48%) of the 96 co-
infected patients (genotype 1 = 19, genotype 2 or 3 = 12,
and genotype 4 = 15). Antiretroviral therapy had to be
modified prior to or during HCV treatment in 17 patients
(37%) because of drug interactions. Psychotropic drugs
had to be administered in 15 patients and methadone
maintenance therapy in another six. Doses of ribavirin
and/or interferon had to be reduced in 12 patients, mainly
for anemia. Ribavirin had to be prematurely discontinued
in four patients and both ribavirin and interferon in
another six (including two drop-outs and two deaths).
Severe treatment-related complications were observed in
16 patients: decrease of CD4 count to < 200/mm3 (n = 7),
thyroid disorder (n = 3), severe anemia (n = 3), acute psy-
chosis (n = 2) and protracted neuritis (n = 1). In June
2008, eight patients were on ongoing treatment/early fol-
low-up. Of the remaining 38 treated patients, sustained
viral response was obtained in 12 (32%) patients (4/16
with genotype 1 [25%]; 6/9 with genotype 2 or 3 [67%]
and 2/13 with genotype 4 [15%]). Other outcomes were
non-responder at week 12 (n = 6), non-responder at week
24 (n = 8), breakthrough at week 48 (n = 3), relapse after
6 months (n = 5), drop out (n = 2) and death (n = 2).
Conclusion
Management of HCV/HIV co-infection was extremely
complex even in our highly specialized setting. In addi-
tion, the response rate to HCV therapy was disappoint-
ingly low in comparison with published trials. Better
therapies are urgently needed, especially for HCV geno-
types 1 and 4.
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